Содержание материала


1. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten

GA, et al. Declining morbidity and mortality among patients with advanced

human immunodeficiency virus infection. HIV Outpatient Study

Investigators. N Engl J Med 1998;338:853-60.

2. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath

C, et al. Randomised placebo-controlled trial of ritonavir in advanced

HIV-1 disease. The Advance HIV Disease Ritonavir Study

Group. Lancet 1998;351:543-9.

3. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier

JS, et al. A controlled trial of two nucleoside analogues plus indinavir

in persons with human immunodeficiency virus infection and CD4 cell

counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group

320 Study Team. N Engl J Med 1997;337:725-33.

4. Van Cleef G, Fisher EJ, Polk RE. Drug interaction potential with inhibitors

of HIV protease. Pharmacotherapy 1997;17:774-8.

5. Preston SL, Postelnick M, Purdy BD, Petrolati J, Aasi H, Stein DS. Drug

interactions in HIV-positive patients initiated on protease inhibitor therapy

(letter). AIDS 1998;12:228-30.

6. von Moltke LL, Greenblatt DY, Grassi JM, Granda BW, Duan SX, Fogelman

SM, et al. Protease inhibitors as inhibitors of human cytochromes

P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-


7. von Moltke LL, Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX,

Daily JP, et al. Inhibition of cytochrome P450 isoforms by nonnucleoside

reverse transcriptase inhibitors. J Clin Pharmacol 2001;41:85-91.

8. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a

review for clinicians. JAMA 1997;277:145-53.

9. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients

with HIV disease. Clinically important pharmacokinetic considerations.

Clin Pharmacokinet 1997;32:194-209.

10. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions

in patients infected with HIV. Clin Infect Dis 1996;23:685-93.

11. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics

and potential interactions amongst antiretroviral agents used to treat patients

with HIV infection. Clin Pharmacokinet 1999;36:289-304.

12. Tseng AL, Foisy MM. Management of drug interactions in patients with

HIV. Ann Pharmacother 1997;31:1040-58.

13. Product monograph. Sustiva (efavirenz). Princeton, NJ: Bristol Myers

Squibb Pharma, February 2002.

14. Patrick DM, Strathdee SA, Currie S, Pitchford W, Rekart ML, FitzGerald

M, et al. Incidence of HIV in the Vancouver IDU Study Cohort. Presented

at: 6th Annual Canadian Conference on HIV/AIDS Research, Ottawa,

May 22–26, 1997.

15. Clarke S, Quah S, Courtney G, Lyons F, Bergin C, Mulcahy F. A rapidly

increasing incidence of HIV infection in injecting drug users (IDU) in

Ireland (abstract). Presented at: 8th Conference on Retroviruses and Opportunistic

Infections, Chicago, February 4–8, 2001.

16. HIV/AIDS surveillance report. Atlanta: Centers for Disease Control and

Prevention, 2001;13:1- 41.

17. Geduld J, Archibald C. National trends of HIV and AIDS in Canada .

Canada Commun Dis Rep 2000;26:193-201.

18. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA.

Lancet 1998;352:1751-2.

19. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the

likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet


20. Jacobs MR, O’Brien Fehr K. Drugs and drug abuse: a reference text.

Toronto: Alcoholism and Drug Addiction Research Foundation, 1987.

21. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, et al.

The demethylenation of methylenedioxymethamphetamine (“ecstasy”)

by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994;47:


22. Colado MI, Williams JL, Green AR. The hyperthermic and neurotoxic

effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine

(MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer

phenotype. Br J Pharmacol 1995;115:1281-9.

23. Kreth K, Kovar K, Schwab M, Zangar UM. Identification of the human

cytochromes P450 involved in the oxidative metabolism of “Ecstasy”-related

drugs. Biochem Pharmacol 2000;15:1563-71.

24. Sherlock K, Wolff K, Hay AW, Conner M. Analysis of illicit ecstasy

tablets: implications for clinical management in the accident and emergency

department. J Accid Emerg Med 1999;16:194-7.

25. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir,

efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug

interactions with bupropion. Drug Metab Dispos 2001;29:100-2.

26. Lin LY, Kumagai Y, Hiratsuka A, Narimatsu S, Suzuki T, Funae Y, et al.

Cytochrome P4502D isozymes catalyze the 4-hydroxylation of methamphetamine

enantiomers. Drug Metab Dispos 1995;23:610-4.

27. Geertsen S, Foster BC, Wilson DL, Cyr TD, Casley W. Metabolism of

methoxyphenamine and 2-methoxyamphetamine in P4502D6-transfected

cells and cell preparations. Xenobiotica 1995;25:895-906.

28. Lin LY, Di Stefano EW, Schmitz DA, Hsu L, Ellis SW, Lennard MS, et

al. Oxidation of methamphetamine and methylenedioxymethamphetamine

by CYP2D6. Drug Metab Dispos 1997;25:1059-64.

29. Lettieri JT, Fung HL. Dose-dependent pharmacokinetics and hypnotic

effects of sodium gamma-hydroxybutyrate in the rat. J Pharmacol Exp

Ther 1979;208:7-11.

30. Lettieri JT, Fung HL. Absorption and first pass metabolism of 14C-gamma-

hydroxybutyric acid. Res Commun Chem Pathol Pharmacol 1976;


31. Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening

interactions between HIV-1 protease inhibitors and the illicit drugs

MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999;159:2221-


32. White PF, Way WL, Trevor AJ. Ketamine — its pharmacology and therapeutic

uses. Anesthesiology 1982;56:119-36.

33. Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y,

et al. Involvement of CYP2B6 in n-demethylation of ketamine in human

liver microsomes. Drug Metab Dispos 2001;29:887-90.

34. Loch JM, Potter J, Bachman KA. The influence of anesthetic agents on

rat hepatic cytochromes P450 in vivo. Pharmacology 1995;50:146-53.

35. Menuguz A, Fortuna S, Lorenzini P, Volpe MT. Influence of urethane

and ketamine on rat hepatic cytochrome P450 in vivo. Exp Toxicol

Pathol 1999;51:392-6.

36. Laurenzana EM, Owens SM. Metabolism of phencyclidine by human

liver microsomes. Drug Metab Dispos 1997;25:557-63.

37. Shelnutt SR, Badger TM, Owens SM. Phencyclidine metabolite irreversible

binding in the rat: gonadal steroid regulation and CYP2C11. J

Pharmacol Exp Ther 1996;277:292-8.

38. Crowley JR, Hollenberg PF. Mechanism-based inactivation of rat liver

cytochrome P4502B1 by phencyclidine and its oxidative product, the

iminium ion. Drug Metab Dispos 1995;23:786-93.

39. Inoue T, Niwaguchi T, Murata T. Effects of inducers and/or inhibitors on

metabolism of lysergic acid diethylamide in rat liver microsomes. Xenobiotica


40. Cai J, Henion J. Elucidation of LSD in vitro metabolism by liquid chromatography

and capillary electrophoresis coupled with tandem mass

spectrometry. J Anal Toxicol 1996; 20:27-37.

41. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, et al. Involvement

of cytochrome P450 3A4 enzyme in the N-demethylation of

methadone in human liver microsomes. Chem Res Toxicol 1996;9:365-


1610 The Annals of Pharmacotherapy 2002 October, Volume 36 www.theannals.com

T Antoniou and AL Tseng

42. Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human

liver microsomes: lack of stereoselectivity and involvement of

CYP3A4. Br J Clin Pharmacol 1999;47:403-12.

43. Eap CB, Broly F, Mino A, Hammig R, Deglon JJ, Uehlinger C, et al. Cytochrome

P450 2D6 genotype and methadone steady-state concentrations.

J Clin Psychopharmacol 2001;21:229-34.

44. Gerber JG, Rhodes RJ. Cytochrome P450 2B6 metabolizes methadone

preferentially and stereospecifically. An explanation of drug interaction

with antiretroviral drugs (abstract 2.2). Presented at: First International

Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the

Netherlands , March 30–31, 2000:14.

45. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG,

et al. The pharmacokinetics of methadone in HIV-positive patients receiving

the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J

Clin Pharmacol 2001;51:213-7.

46. Heelon MW, Meade LB. Methadone withdrawal when starting an

antiretroviral regimen including nevirapine. Pharmacotherapy 1999;19:471-


47. Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB.

Efavirenz decreases methadone blood concentrations. AIDS 2000;14:1291-


48. Pinzani V, Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal

symptoms with nevirapine and efavirenz (letter). Ann Pharmacother


49. Staszewski S, Haberl A, Gute P, Nisius G, Miller V, Carlebach A.

Nevirapine/didanosine/lamivudine once daily in HIV-1 infected intravenous

drug users. Antiviral Ther 1998; 3:55-6.

50. Altice FL, Friedland GH, Cooney E. Nevirapine induced opiate withdrawal

among injection drug users with HIV infection receiving

methadone. AIDS 1999;13:957-62.

51. Otero MJ, Fuertes A, Sanchez R, Luna G. Nevirapine-induced withdrawal

symptoms in HIV patients on methadone maintenance programme:

an alert. AIDS 1999;13:1004-5.

52. Geletko SM, Erickson AD. Decreased methadone effect after ritonavir

initiation. Pharmacotherapy 2000;20:93-4.

53. Hsyu PH, Lillibridge JH, Maroldo L, Weiss WR, Kerr BM. Pharmacokinetic

and pharmacodynamic interactions between nelfinavir and methadone

(abstract 87). Presented at: 7th Conference on Retroviruses and Opportunistic

Infections, San Francisco, January 30– February 2, 2000.

54. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D’Amico R, Mildvan D, et

al. The effect of ritonavir/saquinavir on the stereoselective pharmacokinetics

of methadone: results of AIDS clinical trials group (ACTG) 401. J

Acq Immune Def Synd 2001;27:153-60.

55. Hendrix C, Wakeford J, Wire MB, Bigelow G, Cornell E, Christopher J,

et al. Pharmacokinetic and pharmacodynamic evaluation of methadone

enantiomers following co-administration with amprenavir in opioid-dependent

subjects (abstract 1649). Presented at: 40th Interscience Conference

on Antimicrobial Agents and Chemotherapy, Toronto, September

17–20, 2000:335.

56. Maroldo L, Manocchio S, Artenstein A, Weiss W. Lack of effect of nelfinavir

mesylate on maintenance methadone dose requirement (abstract

WePeB4120). Presented at: XIII International AIDS Conference, Durban,

South Africa , July 9–14, 2000:60.

57. McCance-Katz EF, Farber S, Selwyn PA, O’Connor A. Decrease in

methadone levels with nelfinavir mesylate (letter). Am J Psychiatry


58. Beauverie P, Taburet AM, Dessalles MC, Furlan V, Touzeau D. Therapeutic

drug monitoring of methadone in HIV-infected patients receiving

protease inhibitors. AIDS 1998;12:2510-1.

59. Rainey PM, Friedland G, McCance-Katz EF, Andrews L, Mitchell SM,

Charles C, et al. Interaction of methadone with didanosine and stavudine.

J Acq Immune Def Synd 2000;24:241-8.

60. Schwartz EL, Brechbuhl AB, Kahl P, Miller MA, Selwyn PA, Friedland

GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous

drug–using patients with HIV infection. J Acq Immune Def

Synd 1992;5:619-26.

61. McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects

on zidovudine disposition (AIDS clinical trials group 262). J Acq

Immune Def Synd 1998;18:435- 43.

62. Sellers E, Lam R, McDowell J, Corrigan B, Hedayetullah N, Somer G,

et al. The pharmacokinetics of abacavir and methadone following coadministration:

CNAA1012 (abstract 663). Presented at: 39th Interscience

Conference on Antimicrobial Agents and Chemotherapy, San Francisco,

September 26–28, 1999:25.

63. Booker B, Smith P, Forrest A, Difrancesco R, Morse G, Cottone P, et al.

Lack of effect of methadone (MET) on the pharmacokinetics (PK) of

delavirdine (DLV) & N-delavirdine (abstract A 490). Presented at: 41st

Interscience Conference on Antimicrobial Agents and Chemotherapy,

Chicago, December 16–19, 2001:14.

64. Boffito M, Rossati A, Dal Conte I, Reynolds H, Gibbons S, Back D, et

al. Opiate withdrawal syndrome in new efavirenz recipients under

methadone maintenance regimen (abstract). Presented at: 1st IAS Conference

on HIV Pathogenesis and Treatment, Buenos Aires, July 8–11,


65. Smith PF, Booker BM, Difrancesco R, Morse GD, Cottone PF, Murphy

MK, et al. Effect of methadone or LAAM on the pharmacokinetics of

nelfinavir & M8 (abstract A- 491). Presented at: 41st Interscience Conference

on Antimicrobial Agents and Chemotherapy, Chicago, December

16–19, 2001:14.

66. Brown LS, Chu M, Aug C, Dabo S. The use of nelfinavir and two nucleosides

concomitantly with methadone is effective and well-tolerated in

HepC co-infected patients (abstract I-206). Presented at: 41st Interscience

Conference on Antimicrobial Agents and Chemotherapy, Chicago,

December 16–19, 2001:311.

67. Shelton MJ, Cloen D, Berenson C, Esch A, Brewer J, Hewitt R. Pharmacokinetics

(PK) of once daily (QD) saquinavir/ritonavir (SQV/RTV): effects

on unbound methadone and á-acid glycoprotein (AAG) (abstract

A-492). Presented at: 41st Interscience Conference on Antimicrobial

Agents and Chemotherapy, Chicago, December 16–19, 2001:14.

68. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG,

et al. Pharmacokinetic interactions of nevirapine and methadone and

guidelines for use of nevirapine to treat injection drug users. Clin Infect

Dis 2001;33:1595-7.

69. Cantilena L, McCrea J, Blazes D, Winchell G, Carides A, Royce C, et al.

Lack of a pharmacokinetic interaction between indinavir and methadone

(abstract PI-74). Clin Pharmacol Ther 1999;65:135.

70. Clarke S, Mulcahy F, Bergin C, Reynolds H, Boyle N, Barry MG, et al.

Absence of opioid withdrawal symptoms in patients receiving methadone

and the protease inhibitor lopinavir–ritonavir. Clin Infect Dis 2002;34:


71. Munsiff AV, Patel J. Regimens with once daily ritonavir + Fortovase are

highly effective in PI-experienced HIV-HCV co-infected patients on

methadone (abstract 684). Presented at: 39th Annual Meeting of the Infectious

Diseases Society of America , San Francisco, October 25–28, 2001.

72. Friedland G, Rainey P, Jatlow P, Andrews L, Damle B, McCance-Katz

E. Pharmacokinetics (pK) of didanosine (ddI) from encapsulated enteric

coated bead formulation (EC) vs chewable tablet formulation in patients

(pts) on chronic methadone therapy (abstract TuPeB4548). Presented at:

XIV International AIDS Conference, Barcelona, July 7–12, 2002, vol


73. Guibert A, Furlan V, Martino J, Taburet AM. In vitro effect of HIV protease

inhibitors on methadone metabolism (abstract). Presented at: 37th

Interscience Conference on Antimicrobial Agents and Chemotherapy,

Toronto, September 28– October 1, 1997.

74. Hsu A, Granneman GR, Carothers L, Dennis S, Chiu Y-L, Valdes J, et al.

Ritonavir does not increase methadone exposure in healthy volunteers

(abstract 342). Presented at: 5th Conference on Retroviruses and Opportunistic

Infections, Chicago, February 1–5, 1998.

75. Boulton DW, Arnaud P, DeVane CL. A single dose of methadone inhibits

cytochrome P- 4503A activity in healthy volunteers as assessed by

the urinary cortisol ratio. Br J Clin Pharmacol 2001;51:350-4.

76. Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of

methadone with substrates of human hepatic cytochrome P450 3A4.

Toxicology 1997;117:13-23.

77. Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, et al. Inhibition

of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J

Clin Pharmacol 1993;35:30-4.

78. Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, et al. Circulating

metabolites of the human immunodeficiency virus protease inhibitor

nelfinavir in humans: structural identification, levels in plasma,

and antiviral activities. Antimicrob Agents Chemother 2001;45:1086-93.

79. Edwards DJ, Svensson CK, Visco JP, Lalka D. Clinical pharmacokinetics

of pethidine. Clin Pharmacokinet 1982;7:421-33.

80. Zhang J, Burnell JC, Dumaual N, Bosron WF. Binding and hydrolysis of

meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp

Ther 1999;290:314-8.

81. Piscitelli S, Rock-Kress D, Bertz R, Pau A, Davey R. The effect of ritonavir

on the pharmacokinetics of meperidine and normeperidine. Pharmacotherapy


Recreational Drug–Antiretroviral Agent Interactions

The Annals of Pharmacotherapy 2002 October, Volume 36 1611 www.theannals.com

82. Dayer P, Desmeules J, Striberni R. In vitro forecasting of drugs that

may interfere with codeine bioactivation. Eur J Drug Metab Pharmacokinet


83. Poulsen L, Brosen K, Arendt-Neilsen L, Gram LF, Elbaek K, Sindrup

SH. Codeine and morphine in extensive and poor metabolizers of

sparteine: pharmacokinetics, analgesic effect and side effects. Eur J

Clin Pharmacol 1996;51:289-95.

84. Caraco Y, Tateishi T, Guengerich FP, Wood AJ. Microsomal codeine Ndemethylation:

cosegregation with cytochrome P4503A4 activity. Drug

Metab Dispos 1996;24:761-4.

85. Yue QY, Sawe J. Different effects of inhibitors on the O- and Ndemethylation

of codeine in human liver microsomes. Eur J Clin Pharmacol


86. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determinants of

codeine induction by rifampin: the impact on codeine’s respiratory, psychomotor

and miotic effects. J Pharmacol Exp Ther 1997;281:330-6.

87. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the

effects of codeine and prediction of drug interactions. J Pharmacol Exp

Ther 1996;278:1165-74.

88. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the

pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol

Ther 1998;64:603-11.

89. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes

morphine glucuronidation. Drug Metab Dispos 1997;25:1-4.

90. Fromm MF, Eckhardt K, Li S, Schanzle G, Hofmann U, Mikus G, et al.

Loss of analgesic effect of morphine due to coadministration of rifampin.

Pain 1997;72:261-7.

91. Osborne R, Joel S, Trew D, Slevin M. Analgesic activity of morphine-

6-glucuronide (letter). Lancet 1988;1:828.

92. Chaisson MA, Stoneburner RL, Hildebrandt DS, Ewing WE, Telzak

EE, Jaffe HW. Heterosexual transmission of HIV-1 associated with the

use of smokable freebase cocaine (crack). AIDS 1991;5:1121-6.

93. Edlin BR, Irwin KL, Faruque S, McCoy CB, Word C, Serrano Y, et al.

Intersecting epidemics — crack cocaine use and HIV infection among

inner-city young adults. Multicenter Crack Cocaine and HIV Infection

Study Team. N Engl J Med 1994;331:1422-7.

94. Nuttbrock L, Rosenblum A, Magura S, McQuistion HL, Joseph H. The

association between cocaine use and HIV/STDs among soup kitchen

attendees in New York City. J Acq Immune Def Synd 2000;25:86-91.

95. Inaba T, Stewart DJ, Kalow W. Metabolism of cocaine in man. Clin

Pharmacol Ther 1978;23:547-52.

96. Cone EJ, Tsadik A, Oyler J, Darwin WD. Cocaine metabolism and urinary

excretion after different routes of administration. Ther Drug Monit


97. Stewart DJ, Inaba T, Lucassen M, Kalow W. Cocaine metabolism: cocaine

and norcocaine hydrolysis by liver and serum esterases. Clin

Pharmacol Ther 1979;25:464-8.

98. Leduc BW, Sinclair PR, Shuster L, Sinclair JF, Evans JE, Greenblatt

DJ. Norcocaine and N-hydroxynorcocaine formation in human liver

microsomes: role of cytochrome P- 450 3A4. Pharmacology 1993;46:


99. Ladona MG, Gonzalez ML, Rane A, Peter RM, de la Torre R. Cocaine

metabolism in human fetal and adult liver microsomes is related to cytochrome

P450 3A expression. Life Sci 2000;68:431- 43.

100. Hoffman RS, Henry GC, Howland MA, Weisman RS, Weil L, Goldfrank

LR. Association between life-threatening cocaine toxicity and

plasma cholinesterase activity. Ann Emerg Med 1992;21:247-53.

101. Ndikum-Moffor FM, Schoeb TR, Roberts SM. Liver toxicity from norcocaine

nitroxide, an N-oxidative metabolite of cocaine. J Pharmacol

Exp Ther 1998;284:413-9.

102. Roberts SM, Harbison RD, James RC. Human microsomal N-oxidative

metabolism of cocaine. Drug Metab Dispos 1991;19:1046-51.

103. Pellinen P, Honkakoski P, Stenback F, Niemitz M, Alhava E, Pelkonen

O, et al. Cocaine N-demethylation and the metabolism-related hepatotoxicity

can be prevented by cytochrome P450 3A inhibitors. Eur J

Pharmacol 1994;270:35- 43.

104. Lockridge O, Mottershaw-Jackson N, Eckerson HW, La Du BN. Hydrolysis

of diacetylmorphine (heroin) by human serum cholinesterase. J

Pharmacol Exp Ther 1980;21:1-8.

105. Inturrisi CE, Max MB, Foley KM, Schultz M, Shin SU, Houde RW.

The pharmacokinetics of heroin in patients with chronic pain. N Engl J

Med 1984;310:1213-7.

106. Kamendulis LM, Brzezinski MR, Pindel EV, Bosron WF, Dean RA.

Metabolism of cocaine and heroin is catalyzed by the same human liver

carboxylesterases. J Pharmacol Exp Ther 1996;279:713-7.

107. Jenkins AJ, Keenan RM, Henningfield JE, Cone EJ. Pharmacokinetics

and pharmacodynamics of smoked heroin. J Anal Toxicol 1994;18:317-


108. Busto UE. Benzodiazepines: the science and the myths. Can J Clin

Pharmacol 1999;6:185-6.

109. Kronback T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation

of midazolam and triazolam by human liver cytochrome P450IIIa4.

Mol Pharmacol 1989;36:89-96.

110. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI. Alprazolam

is another substrate for human cytochrome P450-3A isoforms

(letter). J Clin Psychopharmacol 1998;18:256.

111. Frye R, Bertz R, Granneman GR, Qian J, Lamm J, Dennis S, et al. Effect

of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam

(abstract A59). Presented at: 37th Interscience Conference on

Antimicrobial Agents and Chemotherapy, Toronto, September 28–October

1, 1997.

112. Greenblatt D, Moltke L, Harmatz J, Durol AL, Daily JP, Graf JA, et al.

Alprazolam–itonavir interaction: implications for product labeling. Clin

Pharmacol Ther 2000;67:335- 41.

113. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir

on the pharmacokinetics and pharmacodynamics of oral and intravenous

midazolam. Clin Pharmacol Ther 1999;66:33-9.

114. Merry C, Mulcahy F, Barry M, Gibbons S, Back D. Saquinavir interaction

with midazolam: pharmacokinetic considerations when prescribing

protease inhibitors for patients with HIV disease (letter). AIDS 1997;11:


115. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf

JA, et al. Differential impairment of triazolam and zolpidem clearance

by ritonavir. J Acq Immune Def Synd 2000;24:129-36.

116. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive

impairment of triazolam and alprazolam clearance by short-term

low-dose ritonavir: the clinical dilemma of concurrent inhibition and

induction. J Clin Psychopharmacol 1999;19:293-6.

117. Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA. Identification of

the human and animal hepatic cytochromes P450 involved in clonazepam

metabolism. Fundam Clin Pharmacol 1993;7:69-75.

118. Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt

DJ. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation

and demethylation of flunitrazepam. Drug Metab Dispos 2001;29:

133- 40.

119. Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ,

et al. Human liver microsomal diazepam metabolism using cDNA expressed

cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily.

Xenobiotica 1996;26:1155-66.

120. Jung F, Richardson TH, Raucy JL, Johnson EF. Diazepam metabolism

by cDNA-expressed human 2C P450s: identification of P4502C18 and

P4502C19 as low K(M) diazepam N-demethylases. Drug Metab Dispos


121. Patwardhan RV, Yarborough GW, Desmond PV, Johnson RF, Schenker

S, Speeg KVJ. Cimetidine spares the glucuronidation of lorazepam and

oxazepam. Gastroenterology 1980;79:912-6.

122. Ghabrial H, Desmond PV, Watson KJ, Gijsbers AJ, Harman PJ, Breen

KJ, et al. The effects of age and chronic liver disease on the elimination

of temazepam. Eur J Clin Pharmacol 1986;30:93-7.

123. Health Canada . Canada ’s alcohol and other drugs survey. 1995;77:1-6.

124. Lemberger L. Tetrahydrocannabinol metabolism in man. Drug Metab

Dispos 1972;1:461-8.

125. Lemberger L, Weiss JL, Watanabe AM, Galanter IM, Wyatt RJ, Cardon

PV. Delta-9-tetrahydrocannabinol. Temporal correlation of the psychologic

effects and blood levels after various routes of administration. N

Engl J Med 1972;30:685-8.

126. Bornheim LM, Lasker JM, Raucy JL. Human hepatic microsomal metabolism

of delta 1-tetrahydrocannabinol. Drug Metab Dispos 1992;20:


127. Watanabe K, Matsunaga T, Yamamoto I, Funae Y, Yoshimura H. Involvement

of CYP2C in the metabolism of cannabinoids by human hepatic

microsomes from an old woman. Biol Pharm Bull 1995;18:1138-


128. Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS,

et al. The effects of cannabinoids on the pharmacokinetics of indinavir

and nelfinavir. AIDS 2002;16:543-50.

129. McDowell JA, Chittick GE, Pilati-Stevens C, Edwards KD, Stein DS.

Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human

immunodeficiency virus–infected adults. Antimicrob Agents

Chemother 2000;44:1686-90.

1612 The Annals of Pharmacotherapy 2002 October, Volume 36 www.theannals.com

T Antoniou and AL Tseng

Recreational Drug–Antiretroviral Agent Interactions

The Annals of Pharmacotherapy 2002 October, Volume 36 1613 www.theannals.com

130. Tanaka E, Misawa S. Pharmacokinetic interactions between acute alcohol

ingestion and single doses of benzodiazepines, and tricyclic and

tetracyclic antidepressants — an update. J Clin Pharm Ther 1998;23:


131. Klotz U, Ammon E. Clinical and toxicological consequences of the inductive

potential of ethanol. Eur J Clin Pharmacol 1998;54:7-12.

132. Kostrubsky VE, Strom SC, Wood SG, Wrighton SA, Sinclair PR, Sinclair

JF. Ethanol and isopentanol increase CYP3A and CYP2E in primary

cultures of human hepatocytes. Arch Biochem Biophys


133. Hsu A, Bertz R, Granneman GR. Assessing ritonavir dose effect on the

pharmacokinetic parameters of protease inhibitors (abstract 3.3). Presented

at: 2nd International Workshop on Clinical Pharmacology of

HIV Therapy, Noordwijk, the Netherlands , April 2– 4, 2001.

134. Degen O, Kurowski M, Van Lunzen J, Schewe CK, Stellbrink H. Amprenavir

and ritonavir: intraindividual comparison of different doses

and influence of concomitant NNRTI on steady-state pharmacokinetics

in HIV-infected patients (abstract 739). Presented at: 8th Conference on

Retroviruses and Opportunistic Infections, Chicago, February 4–8,